Clinical trial
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
NCT00038493 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00038493 |
|---|---|
| Title | Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme |
| Official title | Phase II Evaluation Temozolomide and Farnesyl Transferase Inhibitor (SCH66336) for the Treatment of Recurrent and Progressive Glioblastoma Multiforme |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme |
| Intervention type | Drug |
| Interventions | Temozolomide and SCH66336 |
| Enrollment | 23 |
| Start date | Sep 21, 2001 |
| Primary completion | Aug 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | Jun 3, 2002 |
| Last update posted | Oct 29, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: